Bowhead Specialty
✦ Quant Fair Value how this is computed
- Implied fair-value range of 24.65-53.17, from this stock's own trailing 5-year average P/E applied to trailing EPS.
- Current price is -12.0% below the average-multiple fair value of 38.91.
Valuation each multiple against its own 5-year range
Vs. peers Insurance - Property & Casualty
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Bowhead Specialty (BOW) | 1.13B | 19.35 | 2.50 | 0.00% |
| Chubb Ltd (CB) | 141.99B | 13.03 | 1.94 | 1.07% |
| Progressive (PGR) | 133.67B | 11.66 | 3.88 | 6.01% |
| The Travelers Companies (TRV) | 82.02B | 10.34 | 2.78 | 1.20% |
| Allstate (ALL) | 66.07B | 6.06 | 2.18 | 1.59% |
| WR Berkley (WRB) | 29.09B | 16.56 | 3.03 | 0.49% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 3.3% below Morningstar's fair value estimate.
Fair value
Bowhead Specialty Holdings Inc earns a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 4% discount to our quantitative fair value estimate of $35.37 per share; however, caution is warranted due to this estimate's high uncertainty rating.
The firm's profitability increases our quantitative valuation. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. Reflecting the firm's profitability is its enterprise value to free cash flow ratio of 14.4, which falls in the bottom 30% globally. This can be a sign of operational efficiency and potential for the company to fund growth, pay dividends, or reduce debt without needing additional capital. We believe this is a sign that shares could be undervalued.
On a different note, the firm's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 40.2%, a core component of valuation, sits in the bottom 40% compared with global peers. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which, despite our favorable price/fair value ratio, is a negative attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.
Economic moat
With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. However, its financial health score is strong, suggesting that the company should be well positioned to weather tough times.
By Quantitative Equity Report
Quote time 2026-11-20 20:02:41 · For reference only, not investment advice and not tailored to your situation.
Bowhead Specialty discussion 0 comments